Phase II study with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel with metronomic cyclophosphamide as a preoperative treatment of triple-negative breast cancer

Clinical Breast Cancer

Volumn 15, Issue 4, 2015, Pages 259-265

  Cancello, Giuseppe ^a   Bagnardi, Vincenzo ^b   Sangalli, Claudia ^a   Montagna, Emilia ^a   Dellapasqua, Silvia ^a   Sporchia, Andrea ^a   Iorfida, Monica ^a   Viale, Giuseppe ^a,c   Barberis, Massimo ^a   Veronesi, Paolo ^a,c   Luini, Alberto ^a   Intra, Mattia ^a   Goldhirsch, Aron ^a   Colleoni, Marco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Chemotherapy; Ki 67; Metronomic therapy; Neoadjuvant; Pathological complete response

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; PACLITAXEL; PROGESTERONE RECEPTOR; ANTINEOPLASTIC AGENT;

ADULT; ADVERSE OUTCOME; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BREAST BIOPSY; CANCER ADJUVANT THERAPY; CANCER FATIGUE; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DYSPEPSIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEARTBURN; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; LOW DRUG DOSE; METRONOMIC DRUG ADMINISTRATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; POPULATION; PREOPERATIVE CARE; PREOPERATIVE TREATMENT; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR BIOPSY; VOMITING; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; MIDDLE AGED; NEOADJUVANT THERAPY; PROCEDURES; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84946488526     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2015.03.002     Document Type: Article

References (36)

1. H.D. Bear, S. Anderson, A. Brown, and et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 21 2003 4165 4174
2. I.C. Smith, S.D. Heys, A.W. Hutcheon, and et al. Neoadjuvant chemotherapy in breast cancer: significant enhanced response with docetaxel J Clin Oncol 20 2002 1456 1466
3. G. Von Minckwitz, G. Raab, A. Caputo, and et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group J Clin Oncol 23 2005 2676 2685
4. K.D. Miller, W. McCaskill-Stevens, J. Sisk, and et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer:a randomized pilot trial of the Hoosier Oncology Group J Clin Oncol 17 1999 3033 3037
5. M. Colleoni, G. Viale, D. Zahrieh, and et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment Clin Cancer Res 10 2004 6622 6628
6. L. Gianni, J. Baselga, W. Eiermann, and et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy Clin Cancer Res 11 2005 8715 8721
7. S. Cleator, W. Heller, and R.C. Coombes Triple-negative breast cancer: therapeutic options Lancet Oncol 8 2007 235 244
8. K.R. Bauer, M. Brown, R.D. Cress, C.A. Parise, and V. Caggiano Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so called triple-negative phenotype: a population-based study from the California Cancer Registry Cancer 109 2007 1721 1728
9. R. Dent, M. Trudeau, K.I. Pritchard, and et al. Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 2007 4429 4434
10. L.A. Carey, E.C. Dees, L. Sawyer, and et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2007 2329 2334
11. R. Rouzier, C.M. Perou, W.F. Symmans, and et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 2005 5678 5685
12. C. Liedtke, C. Mazoun, K.R. Hess, and et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 2008 1275 1281
13. C. Mazouni, S.W. Kau, D. Frye, and et al. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor positive breast cancers Ann Oncol 18 2007 874 880
14. M.C. Green, A.U. Buzdar, T. Smith, and et al. Weekly paclitaxel improves pathological complete remission in operable breast cancer when compared with paclitaxel one every 3 weeks J Clin Oncol 23 2005 5983 5992
15. C.R. James, J.E. Quinn, P.B. Mullan, P.G. Johnston, and D.P. Harkin BRCA1, a potential predictive biomarker in the treatment of breast cancer Oncologist 12 2007 142 150
16. F. Bertolini, S. Paul, P. Mancuso, and et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells Cancer Res 63 2003 4342 4346
17. M. Dowsett, I.E. Smith, S.R. Ebbs, and et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer J Natl Cancer Inst 99 2007 167 170
18. M.J. Ellis, Y. Tao, J. Luo, and et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics J Natl Cancer Inst 100 2008 1380 1388
19. E. Montagna, V. Bagnardi, G. Viale, and et al. Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy Ann Oncol 26 2015 307 313
20. G. von Minckwitz, W.D. Schmitt, S. Loibl, and et al. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer Clin Cancer Res 19 2013 4521 4531
21. N. Matsubara, H. Mukai, M. Masumoto, and et al. Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR Breast Cancer Res Treat 147 2014 95 102
22. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, and et al. New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
23. H.M. Kuerer, L.A. Newman, T.M. Smith, and et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 2000 460 469
24. P. Cortazar, L. Zhang, M. Untch, and et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 384 2014 164 172
25. R. Torrisi, A. Balduzzi, R. Ghisini, and et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel Cancer Chemother Pharmacol 62 2008 667 672
26. G. von Minckwitz, A. Schneeweiss, S. Loibl, and et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial Lancet Oncol 15 2014 747 756
27. W.M. Sikov, D.A. Berry, C.M. Perou, and et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance) J Clin Oncol 33 2015 13 21
28. N. Masuda, K. Higaki, T. Takano, and et al. A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer Cancer Chemother Pharmacol 74 2014 229 238
29. E. Montagna, G. Cancello, S. Dellapasqua, E. Munzone, and M. Colleoni Metronomic therapy and breast cancer: a systematic review Cancer Treat Rev 40 2014 942 950
30. R. Steiner Angiostatic activity of anticancer agents in the chick allantoic membrane (CHE-CAM) assay R. Steiner, P.B. Weisz, R. Langer, Angiogenesis: Key Principles - Science - Technology - Medicine 1992 Birkhaeuser Verlag Basel 449 454
31. E. de Azambuja, F. Cardoso, G. de Castro Jr., and et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12155 patients Br J Cancer 96 2007 1504 1513
32. C.D. Archer, M. Parton, I.E. Smith, and et al. Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer Br J Cancer 89 2003 1035 1041
33. P.A. Fasching, K. Heusinger, L. Haeberle, and et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment BMC Cancer 11 2011 486
34. N. Kumaki, S. Umemura, X. Tang, and et al. Alteration of immunohistochemical biomarkers between pre- and post-chemo- therapy: hormone receptors, HER2 and Ki67 Breast Cancer 18 2011 98 102
35. T. Tanei, A. Shimomura, K. Shimazu, and et al. Prognostic significance of Ki67 index after neoadjuvant chemo-therapy in breast cancer Eur J Surg Oncol 37 2011 155 161
36. R.L. Jones, J. Salter, R. A'Hern, and et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer Breast Cancer Res Treat 116 2009 53 68